"We are pleased to receive approval of Bupropion Hydrochloride (XL) tablet product within first review cycle of 10 months from filing date. This product will be a valuable addition to our growing modified release product portfolio in the US market," GPI Executive Director Priyanka Chigurupati stated.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vHJAPMiGL
via IFTTT
0 comments:
Post a Comment